A Biophysical Study of Molecular Interaction of Tucatinib with Bovine Serum Albumin

Ankita Jalan,N. Shaemningwar Moyon
DOI: https://doi.org/10.1002/slct.202402600
2024-09-14
ChemistrySelect
Abstract:The molecular interaction of Tucatinib (TUC), a targeted anti‐cancer drug against HER2+ advanced unresectable breast cancer, with bovine serum albumin (BSA) is investigated. It quenches the intrinsic fluorescence of BSA via static quenching mechanism, and binds to the hydrophobic cleft of subdomain II' of BSA with a moderate binding affinity with interplay of van der Waals and hydrogen bonding interactions. A profound understanding of the binding dynamics of drugs with plasma proteins is highly important as it determines its therapeutical potential. Herein, we have investigated the molecular interaction of Tucatinib (TUC), a novel, primitive and highly selective drug for treatment of HER2+ advanced unresectable breast cancer, with bovine serum albumin (BSA) using multi‐pronged spectroscopic techniques and molecular docking. TUC considerably quenched the intrinsic fluorescence of BSA via static quenching mechanism, and it binds to the hydrophobic cleft of subdomain IIA of BSA with a moderate binding affinity. The thermodynamic analysis revealed the major interplay of van der Waals forces and hydrogen bonding interactions in stabilising the binding. The Förster distance 'r' signifies feasible energy transfer between BSA and TUC. The conformational analyses indicate some alterations in the protein secondary structure as a consequence of some changes in the protein polar environment due to complex formation. The experimental results are supported by docking analyses.
chemistry, multidisciplinary
What problem does this paper attempt to address?